Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses

Stock Track05-08

Corvus Pharmaceuticals' stock plummeted 5.76% during Thursday's intraday trading session. The sharp decline followed the release of the company's first-quarter 2026 financial results.

The clinical-stage biopharmaceutical company reported a net loss of $13.7 million for the quarter, a significant reversal from the net income of $15.2 million recorded in the same period last year. Research and development expenses surged 49% to $11.2 million, primarily driven by higher clinical trial costs for its lead drug candidate soquelitinib and increased personnel-related costs.

While the company's cash position strengthened to $236.7 million following a January financing, the operational results highlighted continued investment in clinical programs amid a widening loss. The earnings per share came in at -$0.15 for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154191914?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-08 04:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154191914","market":"hk","top_or_hot":-1,"title":"Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses","media":"Stock Track","content":"<p>Corvus Pharmaceuticals' stock plummeted 5.76% during Thursday's intraday trading session. The sharp decline followed the release of the company's first-quarter 2026 financial results.</p><p>The clinical-stage biopharmaceutical company reported a net loss of $13.7 million for the quarter, a significant reversal from the net income of $15.2 million recorded in the same period last year. Research and development expenses surged 49% to $11.2 million, primarily driven by higher clinical trial costs for its lead drug candidate soquelitinib and increased personnel-related costs.</p><p>While the company's cash position strengthened to $236.7 million following a January financing, the operational results highlighted continued investment in clinical programs amid a widening loss. The earnings per share came in at -$0.15 for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Corvus Pharmaceuticals Plummets 5.76% Intraday on Widening Q1 Loss and Rising R&D Expenses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-08 04:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Corvus Pharmaceuticals' stock plummeted 5.76% during Thursday's intraday trading session. The sharp decline followed the release of the company's first-quarter 2026 financial results.</p><p>The clinical-stage biopharmaceutical company reported a net loss of $13.7 million for the quarter, a significant reversal from the net income of $15.2 million recorded in the same period last year. Research and development expenses surged 49% to $11.2 million, primarily driven by higher clinical trial costs for its lead drug candidate soquelitinib and increased personnel-related costs.</p><p>While the company's cash position strengthened to $236.7 million following a January financing, the operational results highlighted continued investment in clinical programs amid a widening loss. The earnings per share came in at -$0.15 for the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1154191914","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154191914","pubTimestamp":1778184702,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Corvus Pharmaceuticals' stock plummeted 5.76% during Thursday's intraday trading session. The sharp decline followed the release of the company's first-quarter 2026 financial results.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"个股追踪|Q1亏损扩大研发费用上升Corvus制药盘中暴跌5.76%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1},"content_text":"Corvus Pharmaceuticals' stock plummeted 5.76% during Thursday's intraday trading session. The sharp decline followed the release of the company's first-quarter 2026 financial results.The clinical-stage biopharmaceutical company reported a net loss of $13.7 million for the quarter, a significant reversal from the net income of $15.2 million recorded in the same period last year. Research and development expenses surged 49% to $11.2 million, primarily driven by higher clinical trial costs for its lead drug candidate soquelitinib and increased personnel-related costs.While the company's cash position strengthened to $236.7 million following a January financing, the operational results highlighted continued investment in clinical programs amid a widening loss. The earnings per share came in at -$0.15 for the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154191914","isCrawlerRequest":true}